Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Company Overview

Bio-Rad Laboratories, Inc. is a global life science research and clinical diagnostics company headquartered in Hercules, California. Founded in 1952, the company develops, manufactures and sells products that support scientific research, biotechnology production, medical testing and quality assurance.

Its Life Science segment provides instruments, reagents, consumables and software used in areas such as genomics, proteomics, cell biology, digital PCR, electrophoresis, chromatography and biopharmaceutical manufacturing. Bio-Rad also supplies food and beverage testing products designed to help laboratories identify contaminants and verify product quality.

Through its Clinical Diagnostics segment, Bio-Rad offers systems, reagents and quality-control products for blood typing and transfusion testing, diabetes monitoring, infectious-disease testing, autoimmune diagnostics and other laboratory applications. The company serves research institutions, hospitals, clinical laboratories, biotechnology and pharmaceutical companies, and food manufacturers through operations and distribution networks in markets around the world.

Key Stats

• Today's Range: $353.30 to $379.67
• 50-Day Range: $313.78 to $391.29
• 52-Week Range: $236.73 to $396.23
• Volume: 264,579 shs
• Average Volume: 255,695 shs
• Market Capitalization: $9.52 billion
• P/E Ratio: 43.14
• Dividend Yield: N/A
• Price Target: $343.33
• Consensus Rating: Hold

Bio-Rad Laboratories Stock Analysis - MarketRank™

Bio-Rad Laboratories scored higher than 37% of companies evaluated by MarketBeat, and ranked 718th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.1 / 5
• Analyst Rating: Hold

Consensus Rating

Bio-Rad Laboratories has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 1 buy rating, 4 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Bio-Rad Laboratories is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bio-Rad Laboratories has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -4.20%

Earnings Growth

Earnings for Bio-Rad Laboratories are expected to decrease by -4.20% in the coming year, from $9.28 to $8.89 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Rad Laboratories is 43.14, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.81.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Rad Laboratories is 43.14, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 272.64.

Price to Book Value per Share Ratio

Bio-Rad Laboratories has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

5.36% of the float of Bio-Rad Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Bio-Rad Laboratories has a short interest ratio ("days to cover") of 3.83, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Bio-Rad Laboratories has recently decreased by 11.65%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Rad Laboratories does not currently pay a dividend.

Dividend Growth

Bio-Rad Laboratories does not have a long track record of dividend growth.

News and Social Media

• Score: 2.3 / 5
• News Sentiment: 0.62

News Sentiment

Bio-Rad Laboratories has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Bio-Rad Laboratories this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.34% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 10/02/2026
• Next Earnings (Estimated): 11/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:BIO
• CIK: 12208
• Web: www.bio-rad.com
• Phone: (510) 724-7000
• Fax: 510-741-5817
• Employees: 7,450
• Year Founded: 1952

Price Target and Rating

• Average Price Target for Bio-Rad Laboratories: $343.33
• High Price Target: $370.00
• Low Price Target: $330.00
• Potential Upside/Downside: -3.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.20
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $8.25
• Trailing P/E Ratio: 43.14
• Forward P/E Ratio: 38.35
• P/E Growth: N/A
• Net Income: $759.90 million
• Net Margins: 8.59%
• Pretax Margin: 13.53%
• Return on Equity: 3.54%
• Return on Assets: 2.48%

Debt

• Debt-to-Equity Ratio: 0.11
• Current Ratio: 3.14
• Quick Ratio: 2.33

Sales & Book Value

• Annual Sales: $2.58 billion
• Price / Sales: 3.68
• Cash Flow: $9.44 per share
• Price / Cash Flow: 37.69
• Book Value: $276.16 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 26,740,000
• Free Float: 18,626,000
• Market Cap: $9.52 billion
• Optionable: Optionable
• Beta: 1.07